Activating mutations, gene fusion and overexpression of FGFR3 in bladder cancer have been documented [15], indicating that bladder cancer is a promising indication for the discovery of novel FGFR inhibitors. The gene discussed is FGFR3; the disease is urinary bladder carcinoma.